SYBXOTCPharmaceutical PreparationsFiscal year ends December 31
SYNLOGIC, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.07+0.07 (+7.00%)
Close on Oct 19, 2026
- Market cap
- $13.29M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -442.1% | -43.5% | -8.2% | |
| Return on assets | -37.8% | -35.6% | -5.7% | |
| Current ratio | 3.84 | 12.87 | 4.30 | |
| Interest coverage | -2994.9× | -10077.7× | – | |
| Capex to revenue | 414.6% | 72.5% | – | |
| Diluted shares | 0M | 2M | 12M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Synlogic generated $196.72M from operations and spent $4.15M on capital expenditure, dividends and share buybacks. 39% of that went back into the business.
Generated
$196.72M
Used
$4.15M
Capital expenditure$1.64M39%Dividends$00%Share buybacks$2.52M61%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-291987.5%
×Asset turnover0.00×
×Equity multiplier2.10×
=Return on equity, FY2024-102.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -291987.5% | 0.00× | 2.10× | -102.6% |
| FY2023 | -1817.7% | 0.04× | 1.62× | -106.2% |
| FY2022 | -5605.7% | 0.01× | 1.24× | -57.6% |
| FY2021 | -3452.7% | 0.01× | 1.21× | -46.2% |
| FY2020 | -10857.4% | 0.00× | 1.22× | -43.5% |
| FY2019 | -2309.9% | 0.01× | 1.17× | -36.6% |
| FY2018 | -1922.0% | 0.02× | 1.15× | -46.3% |
| FY2017 | -1652.1% | 0.04× | 1.28× | -86.3% |
| FY2016 | -4719.4% | 0.01× | 11.70× | -442.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$1.01M
- Cash generatingOperating cash flow above zero-$4.36M
- Return on assets improvedROA up on the prior year-30.9% → -5.1%
- Earnings backed by cashOperating cash flow above net income-$4.36M vs -$1.01M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.80 → 4.30
- No dilutionShare count did not rise12M → 12M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00